Lupin announces partnership with Endoceutics for Intrarosa commercialisation; stock trades flat

Lupin announces partnership with Endoceutics for Intrarosa commercialisation; stock trades flat

Abhinav Lahoti
/ Categories: Trending, DSIJ News

Lupin Pharma Canada, a subsidiary of global pharma major Lupin Ltd, today announced a partnership with Endoceutics, a Canadian biotech company that focuses on women’s health, to commercialise Intrarosa® in Canada.   

Intrarosa® is a flagship product of Endoceutic. It is indicated for the treatment of postmenopausal vulvovaginal atrophy offered as a vaginal ovule containing 6.5 mg of Prasterone.  

Speaking on the partnership, Lupin commented that the company pleased to partner with Endoceutics to bring this long-awaited innovative product to the Canadian market. The product will not expand and strengthen its product portfolio into women’s health in Canada but will also cater to satisfy the unmet medical needs. It is estimated that over 50 per cent of postmenopausal women suffer from the symptoms of vulvovaginal atrophy and that less than 10 per cent of these women are treated with prescription medicines.   

The product is approved for commercialisation in the US, Europe, UK, Canada, Hong Kong, Israel, United Arab Emirates, Switzerland, and Macau.  

At 1.33 pm today, the stock of Lupin Ltd was trading at Rs 1,035.00, down by 1.39 per cent on BSE. 

Previous Article Markets pulled back from days high; Aurionpro, Dixon Technologies & Indoco Remedies become highflyers of the day!
Next Article This small-cap stock rallied 56 per cent in last 3 months!
Rate this article:
5.0

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR